<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03210480</url>
  </required_header>
  <id_info>
    <org_study_id>136PO15274</org_study_id>
    <secondary_id>2016-001714-14</secondary_id>
    <nct_id>NCT03210480</nct_id>
  </id_info>
  <brief_title>SALT Study (Switching to the Administration of Lithium Slow -Release Treatment)</brief_title>
  <official_title>Clinical Evaluation of Switching to Lithiofor® (Lithium Sulphate Slow -Release, Li-SR Tablets) From Carbolithium® (Lithium Carbonate Immediate-Release, Li-IR, Capsules) in Bipolar Patients, Poorly Tolerant to Lithium Immediate-release Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mediolanum Cardio Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the tolerability, efficacy and safety of a new lithium&#xD;
      sulphate prolonged release formulation (Lithiofor®) in patients affected by Bipolar Disorder&#xD;
      poor tolerant to lithium immediate-release treatment in terms of lithium-induced tremor when&#xD;
      switched from therapy with a lithium carbonate immediate release formulation (Carbolithium®)&#xD;
      to a new lithium sulphate prolonged release formulation (Lithiofor®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase IV, randomized, open, parallel groups, multicentre, prospective study.&#xD;
&#xD;
      The main purpose of this clinical trial is to evaluate the change in the lithium induced&#xD;
      tremor when switching from Lithium Immediate Release formulation (Carbolithium®) to Lithium&#xD;
      Sulphate prolonged-release formulation (Lithiofor®) in Bipolar Disorder patients, poorly&#xD;
      tolerant to the Lithium Immediate Release treatment. The primary end point will be the&#xD;
      reduction of the lithium induced tremor.&#xD;
&#xD;
      Patients in treatment with lithium carbonate immediate-release (Carbolithium®), will be&#xD;
      enrolled in the study and, after 1 week of maintaining treatment, will be randomly switched&#xD;
      to Lithium prolonged-release formulation or will continue the previous therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor's decision due to slow enrollment rate.&#xD;
  </why_stopped>
  <start_date type="Actual">March 28, 2017</start_date>
  <completion_date type="Actual">September 20, 2019</completion_date>
  <primary_completion_date type="Actual">September 20, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, multicenter, prospective study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of item 2.5 (tremor) in Udvalg for Kliniske Undersøgelser (UKU) scale</measure>
    <time_frame>Baseline - Week 1</time_frame>
    <description>Proportion of patients with an improvement in tremor assessed by the change from baseline of item 2.5 in UKU side-effect rating scale after 1-week treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of item 2.5 (tremor) in Udvalg for Kliniske Undersøgelser (UKU) scale</measure>
    <time_frame>Baseline - Weeks 4 and 12</time_frame>
    <description>Proportion of patients with an improvement in tremor assessed by the change from baseline of item 2.5 in UKU side-effect rating scale after 4- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of item 3.8 in Udvalg for Kliniske Undersøgelser (UKU) scale</measure>
    <time_frame>Baseline - Weeks 1, 4 and 12</time_frame>
    <description>Proportion of patients with a change from baseline of item 3.8 in UKU side-effect rating scale after 1-, 4- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Montgomery-Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>Baseline - Weeks 1, 4 and 12</time_frame>
    <description>Change from baseline of total score in MADRS scale after 1-, 4- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Young Mania Rating Scale (YMRS)</measure>
    <time_frame>Baseline - Weeks 1, 4 and 12</time_frame>
    <description>Change from baseline of total score in YMRS scale after 1-, 4- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Satisfaction Questionnaire for Medication (TSQM) scale</measure>
    <time_frame>Baseline - Weeks 1 and 12</time_frame>
    <description>Change from baseline in each sub-scale of TSQM after 1- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF)</measure>
    <time_frame>Baseline - Weeks 1 and 12</time_frame>
    <description>Change from baseline in Q-LES-Q-SF after 1- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical Global Impression (CGI) scale</measure>
    <time_frame>Baseline - Weeks 1 and 12</time_frame>
    <description>Assessment by the physician of the overall efficacy by CGI scale after 1- and 12-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of treatment-related adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Monitoring of the frequency of adverse events, physical examination, vital signs, ECG, laboratory analyses, plasma Lithium concentration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lithium sulphate prolonged-release 660 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lithium carbonate immediate-release 150 mg and 300 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium sulphate prolonged-release 660 mg</intervention_name>
    <description>Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.</description>
    <arm_group_label>Group 1</arm_group_label>
    <other_name>LITHIOFOR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium carbonate immediate-release 150 mg and 300 mg</intervention_name>
    <description>Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.</description>
    <arm_group_label>Group 2</arm_group_label>
    <other_name>CARBOLITHIUM®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients aged 18 to 65 years (limits included), with no limitation of&#xD;
             race. Female patients with childbearing potential should have a negative pregnancy&#xD;
             test and should not be breastfeeding. Male and female patients should use an&#xD;
             appropriate birth control method.&#xD;
&#xD;
          2. Diagnosis of Bipolar disorder (BD) I or II (as per DSM-5), with or without rapid&#xD;
             cycling.&#xD;
&#xD;
          3. BD patients in treatment with lithium Carbolithium® immediate-release, presenting at&#xD;
             the screening and baseline low tolerability in terms of tremor (tremor severity&#xD;
             assessment ≥ 2 on single item of the UKU side-effect rating scale).&#xD;
&#xD;
          4. MADRS score ≤ 10 and YMRS ≤ 12 at screening and baseline visits.&#xD;
&#xD;
          5. Patients legally capable to give the consent to participate in the study and available&#xD;
             to sign and date the written informed consent.&#xD;
&#xD;
          6. Patient able to understand the study procedures and to comply with protocol&#xD;
             requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Fulfilling criteria for the following disorders: schizophrenia, psychotic and&#xD;
             schizoaffective disorders, unipolar depression; concomitant organic mental disorder or&#xD;
             intellectual disability; history of dementia or cognitive disorders, any&#xD;
             neurodegenerative diseases.&#xD;
&#xD;
          2. Known hypersensitivity or allergy to lithium or to any components of the study&#xD;
             medications.&#xD;
&#xD;
          3. Pharmacological treatments affecting tremor, except for patients treated for at least&#xD;
             2 months before the screening visit (i.e. Beta-blockers; for further details).&#xD;
&#xD;
          4. Known tremor due to irreversible lithium neurotoxicity.&#xD;
&#xD;
          5. Patients at risk for suicidal behaviour.&#xD;
&#xD;
          6. Immunocompromised patients.&#xD;
&#xD;
          7. Acute, or chronic, or recurrent medical conditions that might affect/jeopardize the&#xD;
             study results.&#xD;
&#xD;
          8. Significant liver disease, defined as known active hepatitis or elevated liver enzymes&#xD;
             &gt; 3 times the upper boundary of the normal ranges.&#xD;
&#xD;
          9. Value of creatinine outside the normal ranges and judged clinically relevant by&#xD;
             Investigator.&#xD;
&#xD;
         10. Any contraindication listed in the Summaries of Product Characteristics (SmPC) of&#xD;
             Carbolithium® and lithium sulphate prolonged-release tablets (Lithiofor®).&#xD;
&#xD;
         11. Positive history for drugs.&#xD;
&#xD;
         12. Alcohol abuse.&#xD;
&#xD;
         13. Positive urine drug screen for CNS-active drugs (cocaine, opioids, amphetamines and&#xD;
             cannabinoids) at Visit 0 (screening).&#xD;
&#xD;
         14. Clinically significant abnormalities on physical examination, vital signs, ECG,&#xD;
             laboratory tests prior to screening visit.&#xD;
&#xD;
         15. Inability to comply with the protocol requirements, instructions and study-related&#xD;
             restrictions; e.g. uncooperative attitude, inability to return for study-visits, and&#xD;
             improbability of completing the clinical study.&#xD;
&#xD;
         16. Vulnerable subjects (e.g. persons kept in detention).&#xD;
&#xD;
         17. Participation to an interventional clinical study within 3 months prior to the&#xD;
             screening visit.&#xD;
&#xD;
         18. If Subject is the Investigator or his(her) deputies, first grade relative, research&#xD;
             assistant, pharmacist, study coordinator, other staff or relative thereof directly&#xD;
             involved in the conduct of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ospedale San Giovanni di Dio di Orbetello Unità Funzionale Salute Mentale</name>
      <address>
        <city>Orbetello</city>
        <state>Grosseto</state>
        <zip>58016</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII - Servizio Psichiatrico di Diagnosi e Cura (SPDC 1)</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Azienda Ospedaliera Universitaria San Martino IST - Clinica Psichiatrica</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Pisana - Psichiatria 1</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Andrea - Dip. Di Neuroscienze, Salute mentale e Organi di senso- NESMOS</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Senese - Dip. Interaziendale di salute mentale - Psichiatria</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.angelinipharma.com</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>July 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2017</study_first_posted>
  <last_update_submitted>January 7, 2020</last_update_submitted>
  <last_update_submitted_qc>January 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lithium Sulphate</keyword>
  <keyword>Prolonged release formulation</keyword>
  <keyword>Lithium carbonate</keyword>
  <keyword>Immediate release formulation</keyword>
  <keyword>Bipolar Disorder</keyword>
  <keyword>Tremor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

